The effect of cryopreserved and noncryopreserved stem cells on the outcome of autologous stem-cell transplantation in multiple myeloma patients: A single-center experience

Basit Öğe Kaydı
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridUYSAL, AYŞE/0000-0002-5581-8104
dc.authoridBİÇİM, SOYKAN/0000-0001-7498-344X
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridSARICI, Ahmet/0000-0002-5916-0119
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidUYSAL, AYŞE/HJB-3073-2022
dc.authorwosidBİÇİM, SOYKAN/ACZ-6163-2022
dc.authorwosidKAYA, Emin/W-2951-2017
dc.authorwosidSARICI, Ahmet/ABI-7512-2020
dc.contributor.authorUysal, Ayse
dc.contributor.authorErkurt, Mehmet A.
dc.contributor.authorKuku, Irfan
dc.contributor.authorKaya, Emin
dc.contributor.authorBerber, Ilhami
dc.contributor.authorSarici, Ahmet
dc.contributor.authorBicim, Soykan
dc.date.accessioned2024-08-04T21:01:23Z
dc.date.available2024-08-04T21:01:23Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground The CD34+ stem cells are either noncryopreserved (non-CP) or cryopreserved (CP) in autologous stem-cell transplantation (ASCT). Some retrospective studies have shown that engraftment failure and engraftment rate are similar in CP cells and infusion reactions are lower in CP cells due to the absence of dimethyl sulfoxide. Objective In this study, we presented our clinical experience comparing the outcomes and safety of ASCT with CP and non-CP stem cells. Patients and methods A total of 163 patients were enrolled between January 2019 and June 2021. Duration of neutrophil/platelet engraftment, rates of infusion-related reactions, febrile neutropenia, and duration of hospitalization were compared between the CP and non-CP groups. Results Fifty five (33.7%) received CP cells, 108 (66.3%) received non-CP cells. The median dose of CD34+ cells was similar in both groups (P=0.755). The median duration of neutrophil and platelet engraftment was not statistically significantly different in CP and non-CP groups (P=0.896 and 0.183, respectively). No statistical difference was observed in the median duration of hospitalization between the two groups [CP: 16 (13-26) vs. non-CP: 15 (11-31) days, P=0.124]. The febrile neutropenia rate was higher in the CP group, but there was no statistical difference between the two groups (CP: 56.4% vs. non-CP, 48.1%, P=0.301). The rates of infusion-related reaction such as nausea, vomiting, and rash were higher in the CP group (21.8 vs. 12%), with no statistically significant difference (P=0.159). Conclusion Non-CP cells have similar outcomes to CP cells and lower toxicity than CP cells, which are safe and effective in ASCT.en_US
dc.identifier.doi10.4103/ejh.ejh_2_22
dc.identifier.endpage186en_US
dc.identifier.issn1110-1067
dc.identifier.issn2090-9268
dc.identifier.issue3en_US
dc.identifier.startpage181en_US
dc.identifier.urihttps://doi.org/10.4103/ejh.ejh_2_22
dc.identifier.urihttps://hdl.handle.net/11616/104334
dc.identifier.volume47en_US
dc.identifier.wosWOS:000913684200003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofEgyptian Journal of Haematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectautologous stem-cell transplantationen_US
dc.subjectcryopreserveden_US
dc.subjectengraftmenten_US
dc.subjectinfusion-related reactionen_US
dc.titleThe effect of cryopreserved and noncryopreserved stem cells on the outcome of autologous stem-cell transplantation in multiple myeloma patients: A single-center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu